Head-to-head · WeighScore
Belle Health vs Kongo
By GLP-1 ScorecardUpdated
Score comparison
Kongo has the higher recorded score — 83.8/100 to 73.8/100.
Kongo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Compounded injection plans with written support; confirm the charge, supplied quantity and renewal terms.
Before you choose
Before comparing the headline prices, the Belle Health review and the Kongo review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Belle Health vs Ondra Health and Big Easy Weight Loss vs Kongo compare each of them with another graded program, and the list of alternatives to Belle Health ranks the programs closest to Belle Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Belle Health | Kongo |
|---|---|---|
| WeighScore | 73.8/100 | 83.8/100 |
| Grade | C | B |
| Site position | #50 | #19 |
| Semaglutide | From $93/mo (compounded; supply terms unverified) | $109 one-month plan or $285 every three months advertised; confirm selected charge and supply. |
| Tirzepatide | From $179/mo (compounded; supply terms unverified) | $209 one-month or $387 three-month plan advertised; confirm selected charge and supply. |
| Coverage | All 50 states | All 50 advertised; confirm treatment-specific state availability. |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #50 · C
FDAWarning letter issued to Belle Health LLC dba Belle in February 2026. See the FDA warning-letter database.
Strengths
- Weekly live group sessions with a named registered dietitian are included
- Provider review, nurse support, injection supplies and shipping are included
- Advertises the same price across dose levels
- Terms state telehealth availability in all 50 states
What to consider
- Starting prices do not establish the required supply length, upfront charge or renewal amount
- Compounded medications are not FDA-approved finished products
- Prescription products are nonrefundable after shipment; subscriptions may renew automatically
- FDA issued Belle Health LLC dba Belle a warning letter in February 2026; the letter is public in FDA's warning-letter database
Strengths
- Regular one-month and prepaid totals published
- Medication, care, supplies and shipping advertised included
- Portal cancellation and clinical messaging
What to consider
- Refund and refill cutoffs need confirmation
- Operator and footer entities need clarification
- Assigned clinician and pharmacy not established
- Telephone support marked coming soon
Featured provider
Belle Health
Belle Health scores 73.8/100 (C). Belle offers compounded GLP-1 injections with clinician oversight, nurse support and weekly group dietitian sessions; confirm the supply commitment behind its starting prices.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to Belle Health LLC dba Belle in February 2026. See the FDA warning-letter database.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.